<DOC>
	<DOCNO>NCT02636049</DOCNO>
	<brief_summary>This Phase 1 , open-label , three-period sequential dosing study conduct determine pharmacokinetics Triferic iron administer intravenously ( IV ) healthy adult .</brief_summary>
	<brief_title>Pharmacokinetics Triferic ( Ferric Pyrophosphate Citrate ) Administered Intravenously Healthy Adult Volunteers</brief_title>
	<detailed_description>This Phase 1 , open-label , three-period sequential dosing study conduct primarily determine pharmacokinetics Triferic iron administer intravenously healthy adults.. Participation 5 week total duration include Screening , Baseline , Treatment Period , Follow-up . Following Screening , subject admitted clinic Day -1 , prior Baseline ( Day 1 ) . During Treatment Period , subject receive two dos Triferic . Each subject receive single 6-mg dose Triferic administer IV 3 hour ( hr ) one day ( Day 2 ) , single 35-µg/kg dose Triferic administer IV push follow day ( Day 3 ) . On Day 4 , subject discharge clinic return approximately one week later final Follow-up visit .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Subjects must meet follow criterion eligible inclusion study : 1 . The subject must able provide inform consent personally sign date study write informed consent document complete studyrelated procedure . 2 . The subject must 1865 year age inclusive time consent . 3 . The subject must transferrin saturation ( TSAT ) 1550 % Screening . 4 . The subject must agree discontinue iron preparation 14 day prior Baseline . 5 . If subject female , must premenopausal , nonpregnant nonlactating , least 90 day postpartum ( applicable ) Screening . Women childbearing potential must willing use appropriate birth control entire duration study . 6 . The subject must willing able comply study procedure restriction . 7 . The subject must clinicallysignificant abnormal finding medical history , vital sign , physical examination , clinical laboratory result Screening . 8 . The subject must body mass index ( BMI ) ≤32.0 kg/m2 Screening weigh &gt; 60.0 kg . A subject eligible inclusion study follow criterion apply : 1 . The subject hemoglobin ( Hgb ) concentration &lt; 13.0 g/dL men &lt; 12 g/dL woman Screening . 2 . The subject total iron binding capacity ( TIBC ) &lt; 250 µg/dL Screening . 3 . The subject administration IV oral iron supplement ( include multivitamin iron ) within 14 day prior Baseline . 4 . Subject concurrent recurrent disease ( e.g. , cardiovascular , renal , hepatic , gastrointestinal , malignant , etc . ) could affect action disposition investigational product utilized study , could affect clinical laboratory assessment . 5 . Subject Creactive protein level ( CRP ) &gt; 5 mg/L Screening , rheumatic autoimmune disease require systemic antiinflammatory immunomodulatory therapy . 6 . Subject acute illness within 14 day prior Baseline . 7 . Subject know suspected intolerance hypersensitivity ironcontaining product . 8 . Subject history alcohol substance abuse within past year . 9 . Subject positive screen cotinine drug abuse . 10 . Subject positive HIV , hepatitis B , hepatitis C. 11 . Subject use tobacco form ( e.g. , smoke chew ) nicotinecontaining product form ( e.g. , gum , patch , etc. ) . Exusers must report stop use tobacco least 30 day prior Baseline . 12 . Subject donate blood blood product ( e.g. , plasma platelet ) within 60 day prior Baseline . 13 . Subject participate investigational drug study within 30 day prior Baseline . 14 . Subject pregnant intend become pregnant completing study . 15 . Subject 's current medical status , investigator 's opinion , would preclude participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy adult volunteer</keyword>
</DOC>